Equillium (EQ.O) gets Australian regulatory clearance for first-in-human clinical trial of Eq504
Equillium Inc expects to begin dosing patients in its first-in-human clinical trial of Eq504 in Australia by early November 2026, with topline Phase 1 data expected six months after study initiation.